Niox Group PLC (AIM: NIOX), an Oxford-based medical device company focused on point-of-care fractional exhaled nitric oxide (FeNO) testing for asthma and COPD diagnosis and management, has confirmed the participation of its directors in the company's Tender Offer, originally announced on 29 September 2026. All directors elected to participate in the offer in respect of their Basic Entitlements, with transactions executed on 27 October 2026 at 80 pence per share on the London Stock Exchange. The announcement also provides an update on a related party transaction involving Harwood Capital, a substantial shareholder, which tendered 4,336,495 ordinary shares.

Key Points

  • Niox Group PLC (AIM: NIOX) is an Oxford-based medical device company specialising in FeNO testing for asthma and COPD
  • All directors participated in the Tender Offer at 80 pence per ordinary share, with transactions settled on 27 October 2026
  • Substantial shareholder Harwood Capital tendered 4,336,495 ordinary shares, constituting a related party transaction under AIM Rule 13
  • Investors may watch how post-offer director shareholdings and the Harwood Capital position affect the company's future shareholder register

NIOX Directors Tender Shares at 80p Across the Board on 27 October 2026

All directors of Niox Group participated in the Tender Offer at a price of 80 pence per ordinary share, with transactions conducted on the London Stock Exchange on 27 October 2026. Chairman Ian Johnson tendered 193,361 shares, reducing his holding to 5,014,927 shares, representing 1.24% of voting rights. Chief Executive Officer Jonathan Emms tendered 71,230 shares, retaining 3,520,637 shares at 0.87%. Chief Financial Officer Sarah Duncan tendered 3,824 shares, retaining 99,194 shares. Non-Executive Directors Garry Watts and Nicholas Mills tendered 16,545 and 4,512 shares respectively, with their post-offer holdings representing 0.11% and 0.03% of voting rights.

Persons Closely Associated With Niox Directors Also Participated in the Tender Offer

The announcement confirms that persons closely associated (PCAs) with certain directors also participated in the Tender Offer. Sharon Emms, PCA of Chief Executive Officer Jonathan Emms, tendered 64,166 shares, reducing her holding to just 2,465 shares. James Duncan, PCA of Chief Financial Officer Sarah Duncan, tendered 78 shares, retaining 34,049 shares. Áinne Naylor, PCA of Non-Executive Director Robert Naylor, tendered 1,639 shares, retaining 42,527 shares. All transactions were executed at the same 80 pence price per ordinary share of 0.08 pence nominal value, with ISIN code GB00BJVD3B28.

Harwood Capital's 4.3 Million Shares Tendered Triggers AIM Rule 13 Related Party Disclosure

Niox Group confirms that Harwood Capital, classified as a substantial shareholder under the AIM Rules, tendered 4,336,495 ordinary shares in the Tender Offer. As previously disclosed on 22 October 2026, this participation was deemed to constitute a related party transaction under AIM Rule 13. The independent directors, having consulted with the company's nominated adviser Singer Capital Markets, stated in the announcement that they consider the terms of the transaction to be fair and reasonable insofar as shareholders are concerned. Singer Capital Markets, acting as both nominated adviser and broker, is contactable via its London office.

Niox Group's FeNO Testing Focus Underpins Strategic Context for the Tender Offer

Niox Group operates in the medical device sector, providing point-of-care FeNO testing solutions used in the diagnosis, monitoring and management of asthma and COPD — conditions with significant global patient populations. The company is headquartered in Oxford, UK, and trades on AIM under the ticker NIOX. The Tender Offer, originally announced on 29 September 2026, and the resulting director and substantial shareholder participation, represents a material capital structure event. Investors may watch subsequent regulatory filings and trading updates to assess how the revised shareholder register affects governance and strategic direction at the company.